The emerging Norwegian biotech company Cytovation AS has identified a potent therapeutically-active peptide, CyPep-H1, which has potential in the treatment of cutaneous warts and cancer and should enter clinical studies in the second half of 2018 with the help of NOK30m (€3.2m) raised in a private funding round led by a group of local investors.
Cytovation Identifies Unique Peptide For Treatment Of Cutaneous Warts
Emerging Company Profile: After an early quiet period, Norway's Cytovation has raised funds locally in the past year to support initial clinical studies of a potential first-in-class viralytic and oncolytic peptide.
More from Start-Ups & SMEs
• By
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
More from Business
• By
GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.
• By
With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.
• By
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.